High risk non-muscle invasive bladder cancer (NMIBC) is a recurring and potentially lethal disease. To date, with the exception of radical surgery, there are no validated strategies for patients not responding to intravesical BCG therapy. Immune Checkpoint Inhibitors (ICI) are currently being tested for BCG-resistant NMIBC. We report current available data and ongoing trials exploring the efficacy and safety of ICI in this setting.

Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era / Albisinni, Simone; Martinez Chanza, Nieves; Aoun, Fouad; Diamand, Romain; Mjaess, Georges; Azzo, Jean-Michel; Esperto, Francesco; Bellmunt, Joaquim; Roumeguère, Thierry; DE Nunzio, Cosimo. - In: MINERVA UROLOGY AND NEPHROLOGY. - ISSN 2724-6442. - (2021). [10.23736/S2724-6051.21.04309-5]

Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era

Albisinni, Simone;Esperto, Francesco;DE Nunzio, Cosimo
2021

Abstract

High risk non-muscle invasive bladder cancer (NMIBC) is a recurring and potentially lethal disease. To date, with the exception of radical surgery, there are no validated strategies for patients not responding to intravesical BCG therapy. Immune Checkpoint Inhibitors (ICI) are currently being tested for BCG-resistant NMIBC. We report current available data and ongoing trials exploring the efficacy and safety of ICI in this setting.
2021
checkpoint; bcg; bladder cancer
01 Pubblicazione su rivista::01a Articolo in rivista
Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era / Albisinni, Simone; Martinez Chanza, Nieves; Aoun, Fouad; Diamand, Romain; Mjaess, Georges; Azzo, Jean-Michel; Esperto, Francesco; Bellmunt, Joaquim; Roumeguère, Thierry; DE Nunzio, Cosimo. - In: MINERVA UROLOGY AND NEPHROLOGY. - ISSN 2724-6442. - (2021). [10.23736/S2724-6051.21.04309-5]
File allegati a questo prodotto
File Dimensione Formato  
Albisinni_Immune-checkpoint_2021.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 687.67 kB
Formato Adobe PDF
687.67 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1546194
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 6
social impact